Ocular Proteomics is a research and development company focused on discovery, development and commercialization of biomarkers as a method of improving our understanding of ocular diseases on a molecular level. The companys primary research tool centers on Reverse Phase Protein Microarrays (RPMAs) to analyze longitudinal samples of vitreous humor from patients in key disease demographics, which includes Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). The companys proprietary protein panel measures activated receptor molecules and other markers in the human vitreous.
